ENDPOINTS

Plus, news about Amy­lyx and Sanofi: FDA places hold on Atara Bio­ther­a­peu­tics’ ac­tive INDs: The holds af­fect the T cell ther­a­py that the agency re­ject­ed

Plus, news about Neur­i­zon: WuXi AppTec di­vests again: The com­pa­ny is sell­ing its US med­ical de­vice test­ing op­er­a­tions, in­clud­ing fa­cil­i­ties in Min­neso­ta and Geor­gia to

Plus, news about Ko­di­ak Sci­ences, Out­look Ther­a­peu­tics and Avac­ta: Boehringer In­gel­heim re­ports Phase 3 schiz­o­phre­nia fail: The drug, icleper­tin, Sign up to read this article

Plus, news about In­flam­ma­some Ther­a­peu­tics, John­son & John­son and Ve­rastem: Au­toim­mune dis­ease start­up nabs $30M: Hinge Bio Sign up to read this article for free.

It’s day 3 of the JP Mor­gan Health­care Con­fer­ence, and it’s start­ed to get a lit­tle less crowd­ed in San Fran­cis­co. That said, many small

Plus, news about Biop­ti­mus, RhyGaze, Gri­fols, sub­cu­ta­neous Leqem­bi and Sling Ther­a­peu­tics: Re­gen­eron pours $119.5M in­to Tru­ve­ta Se­ries C: Re­gen­eron will al­so work with the med­ical

We just wrapped day 2 of JPM. We’ve been pay­ing close at­ten­tion to news about the in­dus­try’s biggest drug­mak­ers. Jaimy Lee had a Sign up

Plus, news about Ash­vattha, Bausch + Lomb, White­cap Bio­sciences, Lab­vi­va, Scribe, Sanofi, X4, Apel­lis and Aileron Ther­a­peu­tics: Im­muno­vant nets $450M pri­vate place­ment: The pro­ceeds will

It’s day 1 at the JP Mor­gan Health­care Con­fer­ence, and as the day pro­gressed, new ma­jor themes emerged: What does the morn­ing’s deal­mak­ing tell us

Plus, news about Cri­net­ics, Com­pass Path­ways, Amy­lyx Phar­ma­ceu­ti­cals, Mer­sana Ther­a­peu­tics, Guggen­heim Part­ners, Sci­wind Bio­sciences, 4D Mol­e­c­u­lar Ther­a­peu­tics, Barinthus Bio, Y-mAbs Ther­a­peu­tics and Mei­ji Sei­ka Phar­ma